U.S. FDA Accepts PharmaEssentia’s BLA Resubmission for Ropeginterferon alfa-2b-njft for the Treatment of Polycythemia Vera (PV)

PharmaEssentia Resubmits Application to the U.S. FDA for Ropeginterferon alfa-2b-njft to Treat Polycythemia Vera (PV)

Dr. Norio Komatsu Appointed Chairperson of PharmaEssentia Japan

PharmaEssentia Provides U.S. Regulatory Update on Ropeginterferon alfa-2b-njft for the Treatment of Polycythemia Vera (PV)

PharmaEssentia Initiates Pivotal Trial of Ropeginterferon Alfa-2b to Treat Essential Thrombocythemia

PharmaEssentia to Present at the 39th Virtual Annual J.P. Morgan Healthcare Conference

Five-year Data on Ropeginterferon Alfa-2b Illustrate Durable Response at Five Years in People with Polycythemia Vera

PharmaEssentia to Present Long-Term Data on Ropeginterferon alfa-2b in Polycythemia Vera at Virtual ASH Annual Meeting

PharmaEssentia Appoints Raymond Urbanski, M.D., Ph.D., as U.S. Head of Clinical Development and Medical Affairs

U.S. FDA Accepts PharmaEssentia’s Application for Ropeginterferon Alfa-2b to Treat Polycythemia Vera